Related Experiment Video
Updated: Oct 2, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
A phase IIb study of selinexor in combination with daratumumab in patients with daratumumab-refractory multiple
Noa Biran1, Eli Zolotov2, David Vesole3
1John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA; Division of Multiple Myeloma, Hackensack University Medical Center, Hackensack, NJ, USA; Department of Oncology, Hackensack Meridian School of Medicine, Nutley, NJ. Noa.Biran@hmhn.org.
No abstract available in PubMed .
More Related Videos
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
07:24Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018